Clinical trial
Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated…
NCT00081744 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00081744 |
|---|---|
| Title | Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects |
| Official title | A Multicenter, Double-Blind, Randomized Comparison Study Of the Efficacy and Safety of Tigecycline to Imipenem/ Cilastatin to Treat Complicated Intra-Abdominal Infections in Hospitalized Subjects |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gram-Positive Bacterial Infections, Cross Infection |
| Intervention type | Drug |
| Interventions | Tigecycline |
| Enrollment | 850 |
| Start date | Nov 1, 2002 |
| Primary completion | Aug 1, 2004 |
| Completion | Aug 1, 2004 |
| First posted | Apr 21, 2004 |
| Last update posted | Feb 8, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: